Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Merck scientists present novel inhibitors of factor Xa and/or factor VIIa

Nov. 14, 2002

Initiation of phase III trial of eptifibatide in heart attack

Nov. 13, 2002

APT-3111 awarded E.U. orphan drug status for paroxysmal nocturnal hemoglobinuria

Nov. 12, 2002

Phase II trials initiated with novel anticoagulant rNAPc2

Nov. 11, 2002

Novel factor Xa and/or factor VIIa inhibitors in early development at Merck KGaA

Nov. 6, 2002

Oryx to market Angiomax in Canada

Nov. 5, 2002

Positive phase I results for GH-9001

Oct. 29, 2002

New PAR-1 antagonists prepared and tested at Ortho-McNeil

Oct. 29, 2002

Baxter submits MAA in E.U. for rAHF-PFM

Oct. 25, 2002

New factor Xa inhibitors in early development at Morphochem

Oct. 24, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2026.
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
First cruise ship hantavirus genome points to zoonotic spillover
BioWorld
The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
Makary out at the FDA
BioWorld
U.S. President Donald Trump ended days of rumors and speculation when he confirmed May 12 that Marty Makary is resigning as FDA commissioner. Speaking with...